A clinical model to estimate recurrence risk in resected stage I non-small cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 1, 2008, Pages 22-28

  Goodgame, Boone ^a   Viswanathan, Avinash ^a   Miller, C Ryan ^b   Gao, Feng ^c   Meyers, Bryan ^d,e   Battafarano, Richard J ^d,e   Patterson, Alexander ^d,e   Cooper, Joel ^d,e   Guthrie, Tracey J ^e   Bradley, Jeffrey ^f   Pillot, Giancarlo ^a   Govindan, Ramaswamy ^d,f  

^a Department of Medicine   (United States)

^b Department of Pathology ^*

^c Division of Biostatistics   (United States)

^d USA   (United States)

^e Division of Cardiothoracic Surgery   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Early stage; Non small cell lung cancer; Prognostic index; Recurrence

Indexed keywords

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RECURRENCE; CANCER SURGERY; CELL DIFFERENTIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOBECTOMY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; RECURRENCE RISK; SCORING SYSTEM; SURVIVAL RATE; TUMOR VOLUME; ADENOCARCINOMA; BIOLOGICAL MODEL; CANCER STAGING; COHORT ANALYSIS; LARGE CELL CARCINOMA; LUNG TUMOR; MEDICAL RECORD; MIDDLE AGED; RETROSPECTIVE STUDY; RISK FACTOR; SQUAMOUS CELL CARCINOMA; TUMOR RECURRENCE;

ADENOCARCINOMA; AGED; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MEDICAL RECORDS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 42449129731     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3180ca77d1     Document Type: Article

References (29)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55:10-30.
2. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710-1717.
3. Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumors in resected Stage I lung cancer. J Thorac Cardiovasc Surg. 1995;109:120-129.
4. Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer. 2006;52:207-212.
5. El-Sherif A, Gooding WE, Santos R, et al. Outcomes of sublobar resection versus lobectomy for Stage I non-small cell lung cancer: a 13-year analysis. Ann Thorac Surg. 2006;82:408-415; discussion 415-406.
6. Harpole DH Jr, Herndon JE 2nd, Young WG Jr, et al. Stage I nonsmall cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence. Cancer. 1995;76:787-796.
7. International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351-360.
8. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589-2597.
9. Strauss GMH, Maddaus JE, Johnstone MA, et al. Adjuvant chemotherapy in Stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol. 2006; 24(suppl):7007.
10. Greene FL. AJCC Cancer Staging Manual. New York: Springer-Verlag; 2002.
11. Al-Kattan K, Sepsas E, Fountain SW, et al. Disease recurrence after resection for Stage I lung cancer. Eur J Cardiothorac Surg. 1997;12:380-384.
12. Pasini F, Pelosi G, Valduga F, et al. Late events and clinical prognostic factors in Stage I non small cell lung cancer. Lung Cancer. 2002;37: 171-177.
13. Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al. Molecular pathologic substaging in 244 Stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol. 1998;16:2468-2477.
14. Sawyer TE, Bonner JA, Gould PM, et al. Patients with Stage I non-small cell lung carcinoma at postoperative risk for local recurrence, distant metastasis, and death: implications related to the design of clinical trials. Int J Radiat Oncol Biol Phys. 1999;45:315-321.
15. Battafarano RJ, Piccirillo JF, Meyers BF, et al. Impact of comorbidity on survival after surgical resection in patients with Stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2002;123:280-287.
16. Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion classification in non-small cell lung cancer: a proposal on the basis of outcome assessment. J Thorac Cardiovasc Surg. 2004;127:1574-1578.
17. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac Cardiovasc Surg. 1975;70:606-612.
18. Harrell FE Jr, Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med. 1984;3:143-152.
19. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat Med. 1992;11:2093-2109.
20. Rice D, Kim HW, Sabichi A, et al. The risk of second primary tumors after resection of Stage I nonsmall cell lung cancer. Ann Thorac Surg. 2003;76:1001-1007; discussion 1007-1008.
21. Ahuja V, Coleman RE, Herndon J, et al. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918-924.
22. Downey RJ, Akhurst T, Gonen M, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004 2004;22:3255-3260.
23. 18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-smallcell lung cancer. J Clin Oncol. 2005;23:1136-1143.
24. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucosepositron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol. 1999;17:3201-3206.
25. Pechet TT, Carr SR, Collins JE, et al. Arterial invasion predicts early mortality in Stage I non-small cell lung cancer. Ann Thorac Surg. 2004;78:1748-1753.
26. Ogawa J, Tsurumi T, Yamada S, et al. Blood vessel invasion and expression of sialyl Lewis x and proliferating cell nuclear antigen in Stage I non-small cell lung cancer: relation to postoperative recurrence. Cancer. 1994;73:1177-1183.
27. Ichinose Y, Yano T, Asoh H, et al. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer: an analysis in each pathologic stage. J Thorac Cardiovasc Surg. 1995;110:601-605.
28. Manac'h D, Riquet M, Medioni J, et al. Visceral pleura invasion by non-small cell lung cancer: an underrated bad prognostic factor. Ann Thorac Surg. 2001;71:1088-1093.
29. Park I, Chung KY, Kim KD, et al. Prognostic factors for disease-free survival in pT2N0 non-small cell lung cancer. Asian Cardiovasc Thorac Ann. 2006;14:139-144.